Summary Background A potent P2Y12 inhibitor-based dual antiplatelet therapy is
recommended for up to 1 year in patients with acute coronary syndrome receiving …

Aim Optimal dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary
intervention (PCI) for acute coronary syndrome (ACS) intends to balance ischemic and …

Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the
standard treatment for patients with acute coronary syndrome (ACS) undergoing …

Abstract Aims Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant
ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both …

Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of
treatment to prevent thrombotic complications of acute coronary syndromes and …

Importance Acute coronary syndrome (ACS) is a major cause of morbidity and mortality in
the United States with an annual incidence of approximately 1 million. Dual antiplatelet …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay
of treatment for acute coronary syndrome (ACS) patients, whether they undergo a …

Background Balancing the effects of dual antiplatelet therapy (DAPT) in the era of potent
P2Y12 inhibitors has become a cornerstone of acute coronary syndrome (ACS) …

Background Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus
a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in …